$35M Series C Fuels Octave’s Commercial Momentum in Precision Neurology – Read the Release

OCTAVE EVENTS

Sep 24 - 26, 2025
Barcelona, Spain

Octave at ECTRIMS 2025

Explore Octave's Clinical Research

P1544 – Characterizing Protein and MSDA Score Correlations Amongst Stable Participants from the Measuring Outcomes and Value: an Integrated, Novel Solution for Generating insights in MS (MOVING MS) Study

P263 – Characterizing MSDA Score and MSDA Panel Biomarker Associations with Disease Activity and Progression Measures in the Graz MS Study

P1528 – Real-world Utilization of a Novel Multi-analyte Blood-Based Biomarker Panel, the Octave® Multiple Sclerosis Disease Activity (MSDA) Test In Clinical Practice Across the United States

P767 – Blood Protein Profiles are associated with Brain Atrophy in Multiple Sclerosis

P1533 – Choroid Plexus Volume and Blood-based Protein Profiles to Monitor Brain Atrophy in Multiple Sclerosis

P236 – Temporal Dynamics of Proteomic Profiling in Multiple Sclerosis: Insights from a Retrospective Longitudinal Study

P1947 – Three-Year Findings on the Safety and Efficacy of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Extension Study)

Connect with Octave

Doug Biehn

CEO

Ferhan Qureshi

SVP, Biomarker R&D

Terrie Livingston

VP, Medical Affairs

Olena Stadnyuk

VP, Business Dev.

Jonathan Verrier

Medical Director, MS